Today's Date: June 16, 2021
Students Write Over 2 Million Lines of JavaScript - with Blackbird Code   •   Spelman College Announces $7.5M Gift to Fund Endowed Professorship and Scholarship in The Arts   •   Amazon Studios Releases Inclusion Policy and Playbook to Strengthen Ongoing Commitment to Diverse and Equitable Representation   •   Sentry Becomes Official Title Sponsor Of Wisconsin State Women's Open, Deepens Commitment To Women's Golf   •   Tampax Launches Flow It Forward Scholarship Program With UNCF to Support HBCU Students Pursuing Healthcare Careers   •   FXAIR Launches “Hamptons 10-Pack,” Guaranteed Premium Helicopter Access From New York City to The Hamptons This Summ   •   Celebrate Great Dads This Father’s Day with Amazing Gifts from Macy’s   •   Sun Pop Life Announces Sun-Protective Children's Swimwear Collection Is Now Available   •   Bank of America Announces $4.2 Million Commitment to Expand Tech Career Opportunities for Students of Color Through Innovative P   •   Jacksonville Black Chamber of Commerce Announces New President   •   Announcing June 29 Premiere of the Inaugural 'A Celebration of Black Music: Music is the Window to Our Souls,' Sponsored by Ande   •   ADM Endeavors, Inc. (OTCQB: ADMQ) Helps with Hockey World Record Through Sponsorship   •   Dr. Johnnetta B. Cole Announced as Keynote Speaker for South Florida Institute on Aging’s 5th Annual Symposium   •   UCI Health and CHOC open one of the first fetal care centers in So. Cal   •   Hilton Solves Longtime Travel Frustration by Introducing Confirmed Connecting Rooms   •   Progressive Grocer Reveals Record-Setting 2021 Class of Top Women in Grocery   •   Women of Commonwealth Initiative Emphasizes Commitment to Inclusion and Community   •   Leonardo DRS Announces Support of Homes For Our Troops   •   Experts confirm extremely low levels of fluoride reduce IQ, according to the Fluoride Action Network   •   The Executive Leadership Council Announces "Build, Grow, Protect!" a $6M Philanthropic Investment in Sustainable Strategies To A
Bookmark and Share

Mednax Reports First Quarter Results

FORT LAUDERDALE, Fla. , May 07 /Businesswire/ - Mednax, Inc. (NYSE: MD), the national medical group specializing in prenatal, neonatal, and pediatric services, today reported earnings from continuing operations of $0.06 per share for the three months ended March 31, 2021. On a non-GAAP basis, Mednax reported Adjusted EPS from continuing operations of $0.24.

For the 2021 first quarter, Mednax reported the following results from continuing operations:

  • Net revenue of $447 million;
  • Income from continuing operations of $5 million; and
  • Adjusted EBITDA of $45 million.

“Our operating results for the first quarter of 2021 reflected a meaningful positive trend through the quarter of patient volumes and payor mix,” said Mark S. Ordan, Chief Executive Officer of Mednax. “We believe that along with this trend, our singular focus on supporting our affiliated clinicians and the incredible care they provide to women and children and our efforts to reshape our operating efficiency will enable us to grow and to drive strong results for all stakeholders.”

Operating Results from Continuing Operations – Three Months Ended March 31, 2021

During the 2021 first quarter, Mednax’s operations were negatively impacted by reductions in patient volumes and revenue from the COVID-19 pandemic. However, this impact was less significant than during the fourth quarter of 2020.

Mednax’s net revenue for the three months ended March 31, 2021 was $446.8 million, compared to $441.2 million for the prior-year period. Mednax’s overall same-unit revenue increased by 2.5 percent, slightly offset by net acquisition activity. After adjusting to exclude the leap-year impact of an extra day in the 2020 first quarter results, overall same-unit revenue increased 3.6 percent.

Same-unit revenue from net reimbursement-related factors increased by 5.0 percent for the 2021 first quarter as compared to the prior-year period. The net increase primarily reflects funds received under the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act; modest improvements in managed care contracting; increases in contract and administrative fees; and an approximately 110 basis point increase in the percentage of services reimbursed by commercial and other non-government payors. During the 2021 first quarter, the Company recorded $7.7 million of miscellaneous revenue from the provider relief fund established by the CARES Act, which increased the Company’s same-unit revenue from net reimbursement-related factors by 1.8 percent.

Same-unit revenue attributable to patient volume decreased by 2.5 percent for the 2021 first quarter as compared to the prior-year period, and as compared to a decrease of approximately 6.6 percent for the 2020 fourth quarter. In each case, this decline was primarily attributable to the impacts from the COVID-19 pandemic. After adjusting to exclude the leap-year impact of an extra day in the 2020 first quarter results, overall same-unit revenue attributable to patient volume decreased by 1.4 percent.

Shown below are year-over-year percentage changes in selected same-unit volume statistics for the quarter ended March 31, 2021.

 

 

Actual

 

Leap-year Adjusted

 

 

 

 

 

Hospital-based patient services

 

(4.4

)%

 

(3.3

)%

Office-based patient services

 

3.4

%

 

5.0

%

 

 

 

 

 

Neonatology services (within hospital-based services):

 

 

 

 

 

Total births

 

(1.2

)%

 

(0.1

)%

Neonatal intensive care unit (NICU) days

 

(2.2

)%

 

(1.1

)%

For the 2021 first quarter, practice salaries and benefits expense was $319.0 million, compared to $316.3 million for the prior-year period. This increase primarily reflects increases in variable incentive compensation, based on practice-level revenue and other financial results during the quarter, partially offset by favorable malpractice expense year over year.

For the 2021 first quarter, general and administrative expenses were $66.5 million, as compared to $67.4 million for the prior-year period. This decrease reflects stock-based compensation and salary decreases from net staffing reductions, partially offset by approximately $5 million in expenses incurred as part of the Company’s transitional services being provided to the buyers of the Company’s former anesthesiology and radiology medical groups. Mednax was reimbursed for these transition services expenses and recorded such reimbursement within investment and other income, a component of net non-operating expenses.

For the first quarter of 2021, transformational and restructuring related expenses totaled $4.9 million, compared to $16.1 million for the first quarter of 2020. Of the expense recorded during the first quarter of 2021, $3.7 million related to third-party consulting fees, while the remainder related primarily to contract termination fees and position eliminations.

Adjusted EBITDA from continuing operations, which is defined as earnings from continuing operations before interest, loss on early extinguishment of debt, taxes, depreciation and amortization, and transformational and restructuring related expenses, was $45.5 million for the 2021 first quarter, compared to $33.1 million for the prior-year period. Funds received from the provider relief fund established by the CARES Act impacted Adjusted EBITDA positively by approximately $4 million for the 2021 first quarter.

Depreciation and amortization expense was $8.0 million for the first quarter of 2021 compared to $6.8 million for the first quarter of 2020.

Investment and other income was $6.0 million for the first quarter of 2021 compared to a loss of $1.0 million for the first quarter of 2020. This increase primarily represents the reimbursement related to the transition services being provided to the buyers of the Company’s former anesthesiology and radiology medical groups.

Interest expense was $17.6 million for the first quarter of 2021 compared to $27.7 million for the first quarter of 2020. This decline primarily reflects the Company’s January 7, 2021 redemption of its $750 million in outstanding principle amount of 5.25% senior notes due 2023 (the “2023 Notes”).

Loss on early extinguishment of debt, related to the redemption of the 2023 Notes, was $14.5 million for the first quarter of 2021, which included cash premiums and accelerated amortization of deferred financing costs.

Mednax generated income from continuing operations of $5.4 million, or $0.06 per diluted share, for the 2021 first quarter, based on a weighted average 85.5 million shares outstanding. This compares with a loss from continuing operations of $18.5 million, or $0.22 per diluted share, for the 2020 first quarter, based on a weighted average 82.8 million shares outstanding.

For the first quarter of 2021, Mednax reported Adjusted EPS from continuing operations of $0.24, compared to $0.06 for the first quarter of 2020. For these periods, Adjusted EPS from continuing operations is defined as diluted income from continuing operations per common and common equivalent share excluding non-cash amortization expense, stock-based compensation expense, transformational and restructuring related expenses, loss on early extinguishment of debt and discrete tax items.

Financial Position and Cash Flow – Continuing Operations

Mednax had cash and cash equivalents of $270 million at March 31, 2021, compared to $1.12 billion on December 31, 2020, and net accounts receivable were $246 million. Mednax used $764 million in cash in January 2021 to redeem its $750 million 2023 Notes, including cash premiums and accrued interest.

During the first quarter of 2021, Mednax used cash of $98.9 million to fund continuing operations, compared to a use of $153.0 million during the first quarter of 2020. Mednax typically uses cash during the first quarter of each year as it pays incentive compensation, principally to its affiliated physicians, and employee benefit plan matching contributions that were accrued during the prior year. Additionally, during the first quarter of 2021, the Company used $9.1 million to fund capital expenditures and $6.0 million to fund the acquisition of two physician groups.

At March 31, 2021, Mednax had no outstanding borrowings under its $1.2 billion revolving credit facility and had total debt outstanding of $1.0 billion, consisting solely of its senior notes due 2027, and net debt of $730 million.

Discontinued Operations

Discontinued operations for the three months ended March 31, 2021 reflects adjustments to the loss on sale related to the divestiture of the anesthesiology medical group. Discontinued operations for the three months ended March 31, 2020 includes the operating results of the Company’s former anesthesiology and radiology medical groups.

Non-GAAP Measures

A reconciliation of Adjusted EBITDA from continuing operations and Adjusted EPS from continuing operations to the most directly comparable GAAP measures for the three months ended March 31, 2021 and 2020 is provided in the financial tables of this press release.

Earnings Conference Call

Mednax, Inc. will host an investor conference call to discuss the quarterly results at 9 a.m., ET today. The conference call Webcast may be accessed from the Company’s Website, www.mednax.com. A telephone replay of the conference call will be available from 1:30 p.m. ET today through midnight ET May 22, 2021 by dialing 866.207.1041, access Code 7654508. The replay will also be available at www.mednax.com.

ABOUT MEDNAX

Mednax, Inc. is a national medical group comprised of the nation’s leading providers of physician services. Physicians and advanced practitioners practicing as part of Mednax are reshaping the delivery of care within their specialties and subspecialties, using evidence-based tools, continuous quality initiatives, clinical research and telehealth programs to enhance patient outcomes and provide high-quality, cost-effective care. The Company was founded in 1979, and today, through its affiliated professional entities, Mednax provides services through a network of more than 2,300 physicians in 39 states and Puerto Rico. Additional information is available at www.mednax.com.

Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to the Company’s objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made by the Company’s management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the Company’s most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled “Risk Factors”, as well the Company’s current reports on Form 8-K, filed with the Securities and Exchange Commission, and include the impact of the COVID-19 pandemic on the Company and its financial condition and results of operations; the effects of economic conditions on the Company’s business; the effects of the Affordable Care Act and potential changes thereto or a repeal thereof; the Company’s relationships with government-sponsored or funded healthcare programs, including Medicare and Medicaid, and with managed care organizations and commercial health insurance payors; the Company’s ability to comply with the terms of its debt financing arrangements; the impact of the divestiture of the Company’s anesthesiology and radiology medical groups; the impact of management transitions; the timing and contribution of future acquisitions; the effects of share repurchases; and the effects of the Company’s transformation initiatives, including its reorientation on, and growth strategy for, its pediatrics and obstetrics business.

Mednax, Inc.

Consolidated Statements of Income

(in thousands, except per share data)

(Unaudited)

 

Three Months Ended

March 31,

 

2021

 

2020

 

 

 

 

 

 

Net revenue

$

446,753

 

$

441,245

Operating expenses:

 

 

 

 

 

Practice salaries and benefits

 

319,012

 

 

316,279

Practice supplies and other operating expenses

 

22,212

 

 

23,842

General and administrative expenses

 

66,516

 

 

67,442

Depreciation and amortization

 

8,031

 

 

6,803

Transformational and restructuring related expenses

 

4,878

 

 

16,076

Total operating expenses

 

420,649

 

 

430,442

Income from operations

 

26,104

 

 

10,803

Investment and other income (expense)

 

5,967

 

 

(1,046)

Interest expense

 

(17,645)

 

 

(27,665)

Loss on early extinguishment of debt

 

(14,532)

 

 

Equity in earnings of unconsolidated affiliate

 

495

 

 

494

Total non-operating expenses

 

(25,715)

 

 

(28,217)

Income (loss) from continuing operations before income taxes

 

389

 

 

(17,414)

Income tax benefit (provision)

 

4,955

 

 

(1,085)

Income (loss) from continuing operations

 

5,344

 

 

(18,499)

Income (loss) from discontinued operations, net of tax

 

12,290

 

 

(213)

Net income (loss)

 

17,634

 

 

(18,712)

Net loss attributable to noncontrolling interest

 

8

 

 

Net income (loss) attributable to Mednax, Inc.

$

17,642

 

$

(18,712)

 

 

 

 

 

 

Per common and common equivalent share data (diluted):

 

 

 

 

 

Income (loss) from continuing operations

$

0.06

 

$

(0.22)

Income from discontinued operations

$

0.15

 

$

Net income (loss) attributable to Mednax, Inc

$

0.21

 

$

(0.22)

Weighted average common shares

 

85,491

 

 

82,799

Mednax, Inc.

Reconciliation of Income (Loss) from Continuing Operations

to Adjusted EBITDA from Continuing Operations Attributable to Mednax, Inc.

(in thousands)

(Unaudited)

 

Three Months Ended

March 31,

 

2021

 

 

2020

Income (loss) from continuing operations attributable to Mednax, Inc.

$

5,352

 

$

(18,499)

Interest expense

 

17,645

 

 

27,665

Loss on early extinguishment of debt

 

14,532

 

 

Income tax (benefit) provision

 

(4,955)

 

 

1,085

Depreciation and amortization expense

 

8,031

 

 

6,803

Transformational and restructuring related expenses

 

4,878

 

 

16,076

Adjusted EBITDA from continuing operations attributable to Mednax, Inc.

$

45,483

 

$

33,130

Mednax, Inc.

Reconciliation of Diluted Income (Loss) from Continuing Operations per Share

to Adjusted Income from Continuing Operations Attributable to Mednax, Inc. per Diluted Share (“Adjusted EPS”)

(in thousands, except per share data)

(Unaudited)

 

Three Months Ended

March 31,

 

2021

 

 

2020

Weighted average diluted shares outstanding

85,491

 

 

82,799

 

Income (loss) from continuing operations and diluted income from continuing operations per share attributable to Mednax, Inc.

$

5,352

 

$

0.06

 

 

$

(18,499)

 

$

(0.22)

Adjustments (1):

 

 

 

 

 

 

 

 

 

 

 

 

Amortization (net of tax of $890 and $512)

 

2,672

 

 

0.03

 

 

 

1,535

 

 

0.02

Stock-based compensation (net of tax of $929 and $1,813)

 

2,788

 

 

0.03

 

 

 

5,442

 

 

0.07

Transformational and restructuring expenses (net of tax of $1,219 and $4,019)

 

3,659

 

 

0.04

 

 

 

12,057

 

 

0.15

Loss on early extinguishment of debt (net of tax of $3,633)

 

10,899

 

 

0.13

 

 

 

 

 

Net impact from discrete tax events

 

(5,067)

 

 

(0.05)

 

 

 

4,834

 

STORY TAGS: Technology, Women, Children, Consulting, Professional Services, Software, Audio/Video, Practice Management, Consumer, Health, United States, North America, Florida, Webcast, Conference Call, Earnings,

Video

LIVE VIDEO EVERY SATURDAY


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News